Quick Answer
Caribou Biosciences, Inc. reported Revenue (ASC 606) of $11.16 million for fiscal year 2025.
Caribou Biosciences, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $11.16M | +11.7% |
| 2024 | $9.99M | -71.0% |
| 2023 | $34.48M | +148.9% |
| 2022 | $13.85M | +44.3% |
| 2021 | $9.60M | -22.4% |
| 2020 | $12.36M | +113.6% |
| 2019 | $5.79M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.20M | +8.6% | -17.6% |
| June 30, 2025 | $2.67M | -23.0% | +13.3% |
| March 31, 2025 | $2.35M | -3.1% | +16.3% |
| September 30, 2024 | $2.02M | -91.4% | -41.6% |
| June 30, 2024 | $3.46M | -7.7% | +42.6% |
| March 31, 2024 | $2.43M | -30.6% | -89.7% |
| September 30, 2023 | $23.66M | +616.4% | +530.1% |
| June 30, 2023 | $3.75M | -10.4% | +7.2% |
- Caribou Biosciences, Inc. showed an increase of +11.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, Caribou Biosciences, Inc.’s revenue (asc 606) has grown by 92.8% (from $5.79 million to $11.16 million).
- The most recent figure is from Caribou Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: